3

5

Integrative omics identifies conserved and pathogen-specific responses of sepsis-causing bacteria

4 Supplementary Figures and Tables

Andre Mu^{^,1,2}, William P. Klare^{^,3}, Sarah L. Baines^{^,1}, C.N. Ignatius Pang^{^,4,5}, Romain 6 Guerillot^{^,1}, Nichaela Harbison-Price^{^,6,7}, Nadia Keller⁶, Jonathan Wilksch¹, Nguyen Thi 7 8 Khanh Nhu^{6,7}, Minh-Duy Phan^{6,7}, Bernhard Keller^{6,7}, Brunda Nijagal^{8,9}, Dedreia Tull⁸, Saravanan Dayalan⁸, Hwa Huat Charlie Chua⁸, Dominik Skoneczny⁸, Jason Koval⁴, 9 Abderrahman Hachani¹, Anup D. Shah¹⁰, Nitika Neha¹⁰, Snehal Jadhav¹⁰, Sally R. Partridge¹¹, 10 11 Amanda J. Cork^{6,7}, Kate Peters^{6,7}, Olivia Bertolla^{6,7}, Stephan Brouwer^{6,7}, Steven J. Hancock⁶, Laura Álvarez-Fraga⁶, David M.P. De Oliveira^{6,7}, Brian Forde⁶, Ashleigh Dale³, Warasinee 12 Mujchariyakul¹, Calum Walsh¹, Ian Monk¹, Anna Fitzgerald¹², Mabel Lum¹², Carolina Correa-13 Ospina⁴, Piklu Roy Chowdhury¹³, Robert G. Parton^{7,14}, James De Voss⁶, James Beckett⁶, 14 Francois Monty¹⁵, Jessica McKinnon¹³, Xiaomin Song¹⁶, John R. Stephen¹⁷, Marie Everest¹⁷, 15 16 Matt I. Bellgard¹⁸, Matthew Tinning¹⁷, Michael Leeming⁸, Dianna Hocking¹, Leila Jebeli¹, Nancy Wang¹, Nouri Ben Zakour¹¹, Serhat A. Yasar⁴, Stefano Vecchiarelli⁴, Tonia Russell⁴, 17 Thiri Zaw¹⁶, Tyrone Chen¹⁹, Don Teng^{8,9}, Zena Kassir⁴, Trevor Lithgow²⁰, Adam Jenney²⁰, 18 Jason N. Cole²¹, Victor Nizet²¹, Tania C. Sorrell¹¹, Anton Y. Peleg²⁰, David L. Paterson²², Scott 19 A. Beatson⁶, Jemma Wu¹⁶, Mark P. Molloy¹⁶, Anna E. Syme²³, Robert J.A. Goode^{10,24}, Adam 20 A. Hunter¹⁸, Grahame Bowland¹⁸, Nicholas P. West^{*,6}, Marc R. Wilkins^{*,4}, Steven P. 21 Djordjevic^{*,13}, Mark R. Davies^{*,1}, Torsten Seemann^{*,1}, Benjamin P. Howden^{*,1}, Dana 22 Pascovici^{*,16}, Sonika Tyagi^{*,19}, Ralf B. Schittenhelm^{*,10}, David P. De Souza^{*,8}, Malcolm J. 23 McConville^{*,8,9}, Jonathan Iredell^{*,11}, Stuart J. Cordwell^{*,3}, Richard A. Strugnell^{*,1}, Timothy P. 24 Stinear^{*,1}, Mark A. Schembri^{*,6,7}, Mark J. Walker^{*,+,6,7} 25

26 ^,*Contributed equally to this work

2/ Corresponding autior: Professor Wark J. Warker. Institute for Wolecular Blosc
--

28 University of Queensland, Brisbane, Queensland, Australia; mark.walker@uq.edu.au

29 Author addresses:

30 ¹Department of Microbiology and Immunology, The University of Melbourne at the Peter

- 31 Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- 32 ²Wellcome Sanger Institute, Hinxton, United Kingdom
- ³Charles Perkins Centre and School of Life and Environmental Sciences, The University of
- 34 Sydney, Sydney, New South Wales, Australia
- 35 ⁴Ramaciotti Centre for Genomics, School of Biotechnology and Biomolecular Sciences,
- 36 University of New South Wales, Sydney, New South Wales, Australia
- 37 ⁵Bioinformatics Group, Children's Medical Research Institute, Faculty of Medicine and
- 38 Health, The University of Sydney, New South Wales, Australia
- ⁶Australian Infectious Diseases Research Centre and School of Chemistry and Molecular
- 40 Biosciences, The University of Queensland, Brisbane, Queensland, Australia
- 41 ⁷Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland,
- 42 Australia
- 43 ⁸Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and
- 44 Biotechnology Institute, University of Melbourne, Melbourne, Victoria, Australia
- 45 ⁹Metabolomics Australia, Bio21 Institute, The University of Melbourne, Melbourne, Australia
- 46 ¹⁰Monash Proteomics and Metabolomics Facility, Monash Biomedicine Discovery Institute,
- 47 Monash University, Melbourne, Victoria, Australia
- 48 ¹¹Centre for Infectious Diseases and Microbiology, Westmead Hospital/ Westmead Institute,
- 49 and Sydney ID, University of Sydney, New South Wales, Australia
- ¹²Bioplatforms Australia Ltd., Sydney, New South Wales, Australia

51	¹³ Australian Institute for Microbiology and Infection, University of Technology Sydney, Nev
52	South Wales, Australia

¹⁴Centre for Microscopy and Microanalysis, The University of Queensland, Brisbane,
Queensland, Australia

¹⁵Australian Biocommons, The University of Melbourne, Melbourne, Victoria, Australia

¹⁶Australian Proteome Analysis Facility, Macquarie University, Sydney, Australia

57 ¹⁷Australian Genome Research Facility Ltd., Melbourne, Victoria, Australia

¹⁸Center for Comparative Genomics, Murdoch University, Perth, Western Australia, Australia

¹⁹Department of Infectious Diseases, Monash University, Melbourne, Victoria, Australia

60 ²⁰Centre to Impact AMR and Infection Program, Monash Biomedicine Discovery Institute and

61 Department of Microbiology, Monash University, Melbourne, Victoria, Australia

62 ²¹Department of Pediatrics, University of California at San Diego School of Medicine, La Jolla,

63 CA 92093, USA; Skaggs School of Pharmaceutical Sciences, University of California at San

64 Diego, La Jolla, CA 92093, USA.

65 ²²Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia

²³Melbourne Bioinformatics, The University of Melbourne, Melbourne, Australia

67 ²⁴Present Address: Commonwealth Scientific and Industrial Research Organisation, Clayton,

68 Australia

69

70

- 71
- 72

73

74

76 Supplementary Figures and Tables



















Supplementary Figure 1. Quality control analysis of RNAseq data for each strain included in this study. The following is reported across the six biological replicates per strain for each species when grown in RPMI and exposed to human sera: (A) the number of mapped reads; (B) read counts per million and (C) normalised read counts per million with boxplot markers indicating the median of the data, a box indicating the interquartile ranges, whiskers indicating the minimum and maximum values, and outliers highlighted by individual dots; (D) multi-

dimensional scaling plot visualising the separation in samples by growth in RPMI vs., exposure to human sera along the first dimension; (E) correlation plot of transcriptomic data; (F) detection of outlier samples with boxplot markers indicating the median of the data, a box indicating the interquartile ranges, whiskers indicating the minimum and maximum values, and outliers highlighted by individual dots; and (G) heatmap distribution of gene counts.



107	Supplementary Figure 2. Functional and metabolic pathway enrichment analysis to assess
108	the shared transcriptome response to serum. Shapes and colours represent normalised
109	enrichment scores and indicate up (blue) and down (red) regulated functions or pathways in
110	serum. Only enriched Gene Ontology terms and KEGG metabolic pathways found to be
111	significantly enriched in all strains of a species or 50% of all strains are represented.
112	
113	
114	
115	
116	
117	
118	
119	
120	
121	
122	
123	
124	
125	
126	
127	
128	
129	
130	





132 Supplementary Figure 3. Carbamate kinase augments growth of S. pyogenes in human serum. (A) The arginine deiminase pathway catalyses the conversion of arginine to ornithine 133 134 and carbamoyl phosphate, enabling carbamate kinase mediated ATP, carbon dioxide and 135 ammonia production. (B) Growth rates of GAS 5448 wild type, GAS 5448 *\(\Delta arcC\)*, and GAS 136 5448 $\Delta arcC$ complemented with wild type arcC in human serum. The data corresponds with mean (± SEM) absorbance at 600 nm from three independent biological experiments 137 138 undertaken in technical triplicate. (C) Area-under-the-curve (AUC) for each growth curve was 139 calculated using the R package Growthcurver to compute AUC. Significance testing was

- 140 performed using Student's unpaired, two-sided t-test, with the null with the null hypothesis (no
- 141 difference between mean AUC values) rejected for p < 0.05 (*** p < 0.001) (n=3).



147 Supplementary Figure 4. wcaF and carB gene expression enhances E. coli survival in 148 human serum. Survival of (A) E. coli B36, B36 Δ carB, B36 Δ wcaF, and (B) E. coli EC958, 149 EC958 Δ carB, EC958 Δ wcaF in human serum. The data represents the mean (± SEM) 150 absorbance at 600 nm from three independent biological experiments undertaken in technical 151 triplicate.

























of pro-

Mandae

1000 800

A OFFICIAL

10-10

Į

11111

SSEEEE

NUL CAN

1

3

sondition Press Solu

ill the

tenditor

B sea

167 Supplementary Figure 5. Quality control analysis of metabolomic data for each strain included in this study. The following is reported across the six biological replicates per strain 168

169 for each species when grown in RPMI and exposed to human sera: sample coefficient of 170 variation, number of proteins per sample, samples plotted on PCA sample space, and 171 normalised protein intensities with boxplot markers indicating the median of the data, a box 172 indicating the interquartile ranges, whiskers indicating the minimum and maximum values, and 173 outliers highlighted by individual dots.



192 Supplementary Figure 6. Scatter plots showing the correlation between the DDA and 193 DIA/SWATH proteomic datasets of the 20 pathogens. The log2 fold changes of the two 194 datasets are plotted against each other with the DDA datasets shown on the x-axis and the 195 DIA/SWATH datasets on the y-axis.



216 Supplementary Figure 7. Data-independent acquisition/sequential window acquisition of all 217 theoretical mass spectra (DIA/SWATH) mass spectrometry to assess the impact of serum exposure on proteome within the different species. (A) UpSet plots representing the shared 218 219 and distinctive proteome responses across strains of the same species. Only proteins with 220 significant differential expression after exposure to human serum are represented (FDR<0.05; 221 |log2 fold change|>1). (B) Multidimensional scaling plots of the core-proteins responses across 222 strains of the same species demonstrating a clear separation of serum exposed samples for all 223 species. See Fig. 4 legend for more detailed explanation of the figures.



Supplementary Figure 8. Functional and metabolic pathway enrichment analysis to assess the shared proteome response to serum (DDA mass spectrometry). Shapes and colours represent normalised enrichment scores and indicate up (blue) and down (red) regulated functions or pathways in serum (two-sided Fisher's exact test). Only enriched Gene Ontology terms and KEGG metabolic pathways found to be significantly enriched in all strains of a species or 50% of all strains are represented.



- Supplementary Figure 9. Functional and metabolic pathway enrichment analysis to assess the shared proteome response to serum (DIA/SWATH mass spectrometry). Shapes and colours represent normalised enrichment scores and indicate up (blue) and down (red) regulated functions or pathways in serum (two-sided Fisher's exact test). Only enriched Gene Ontology terms and KEGG metabolic pathways found to be significantly enriched in all strains of a species or 50% of all strains are represented.
- 265



Supplementary Figure 10. Growth kinetics of S. aureus in 50% human serum using S. aureus strain JE2 wild type compared to the JE2 Δ isdI transposon mutant. (A) Growth in RPMI only. (B) Growth in RPMI with 50% heat-treated human serum (v/v). The data in (A) and (B) represents the mean (\pm SEM) absorbance at 600 nm from three independent biological experiments. (C) Comparison of mean area-under-the-curve (AUC) values for each of the three

- 273 biological replicates depicted in (B) showing a significant difference between mutant and wild
- type (two-sided Student's unpaired t-test * p=0.03).



Klebsiella pre

Klebsiella variid



Streptococcus aureus

Streptococcus pyogenes

278 Supplementary Figure 11. Functional and metabolic pathway enrichment analysis to assess

279 *the shared metabolome response to serum (GC-MS)*. Shapes and colours represent normalised

280 enrichment scores and indicate up (blue) and down (red) regulated functions or pathways in

serum. Only enriched Gene Ontology terms and KEGG metabolic pathways found to be

significantly enriched in all strains of a species or 50% of all strains are represented.



Supplementary Figure 12. Stress survival assays following exposure to serum. (A) K.
pneumoniae KPC2; (B) S. pyogenes HKU419; (C) E. coli B36; (D) S. aureus BPH2900 were
incubated in RPMI or serum (5 mL each) for 2 hrs. Cells were collected and then exposed to
either (each graph, left) 150 mM NaCl (osmotic stress), (middle) 5 mM H₂O₂ (oxidative stress),
or (right) 50 µM deferoxamine (DF; iron limitation stress) for 1 hr at 37°C, and survival

- determined by enumeration of CFU. Error bars indicate the mean standard error from 6 biological replicates for all strains and conditions test – except for *S. aureus* BPH2900 tested at 5 mM H₂O₂ in sera and RPMI which had 8 biological replicates – and statistical significance was determined using two-way ANOVA, * p < 0.05; ** p < 0.01, ****p < 0.0001; Holm-*Šidák test.*
- 314



0 minutes

5 minutes



120 minutes



300 minutes





2µm

2µm

2µπ









- 316
- 317

B K. pneumoniae KPC2

0 minutes



C S. aureus BPH2900

0 minutes



D S. pyogenes HKU419

0 minutes





321 Supplementary Figure 13. Quantification of the interaction of bacterial sepsis strains with

- 322 *cholesterol over time.* Indicated bacterial strains were grown for 0 min, 5 min, 120 min or
- 323 300 min in RPMI in the presence of 10µM TopFluor-cholesterol (a fluorescent cholesterol
- analogue). (A-D) Overview (left panel) and close-ups (centre panel) of clinical strains E. coli

325 B36 (A), K. pneumoniae KPC2 (B), S. aureus BPH2900 (C) and S. pyogenes HKU419 (D). 326 Experiments were done at least in three independent biological replicates for time points at 327 120 min for all strains. For the other time points (i.e., 0 min, 5 min, and 300 min) the 328 experiment as performed with at least one independent biological replicate for K. pneumoniae KPC2, E. coli B36, and S. aureus BPH2900, and two independent biological replicates for S. 329 330 pyogenes HKU419. TopFluor-cholesterol is shown in green (GFP), bacteria in red (alexa555) 331 and nuclei in blue (DAPI). Right panel shows the histogram of the fluorescence intensity of 332 one representative bacterium with the cross-section marked in the close-up image. Colours in 333 the histogram are adjusted to microscope pictures with bacteria in red, nuclei in blue and 334 TopFluor-cholesterol in green. 335

338 Supplementary Table 1. Primers used in this study.

GAS 5448				
arcC deletion replacement				
Primers	Sequence $5' \rightarrow 3'$			
CKF	GGGAATTCCAGCTGTTGTCACTCAAGT			
CKR	GGGGATCCACCAGTCAGGG			
CKF-Up	ATGACGAAACAAAAATCGTAGTCGCA			
CKR-Down	TTACCCTGCGATAATTTGTGTTCCAG			
ErmF	ATGAACAAAAATATAAAAATATTCTCAAAAAC			
ErmR	TTATTTCCTCCCGTTAAATAATAGATA			
arcC complementation				
Primers	Sequence $5' \rightarrow 3'$			
arcC_F-Up	GTCGTCAGACTGATGGGCCCCTAAAGATGCTCCCGATG			
arcC_R-Down	CATAACCTGAAGGAAGATCTCATATTAACAACAAGGCCTTC			
arcC_F	AGGAGTAATTATGACGAAACAAAAAATCG			
arcC_R	ATCCTCTTGATTACCCTGCGATAATTTG			
E. coli B36 and E. coli EC958				
Primers	Sequence $5' \rightarrow 3'$			
3518-2394wcaF-Fwsc	AGCGAACCAGATAACGGTA			
3519-2394wcaF-Fwup	ACTCGGGCGATATTTTCAT			
3520-2394wcaF-Rvup	GGAATAGGAACTAAGGAGGACGGCACCGAGAATCCACTTA			
3521-2394wcaF-Fwdn	CCTACACAATCGCTCAAGACTAAATTCAAAAAATACAGAG			
3522-2394wcaF-Rvdn	AACGGCGTGGTCTCTTTCTG			
3523-2394wcaF-Rvsc	CCGTAGGATTCGCGGTAGTT			
11474_carB_Fwup	GTCGCCTGACCATCGTTC			
11475_carB_Rvup	GGAATAGGAACTAAGGAGGATGGCATGGCTCTTTTACTCC			
11476_carB_Fwdn	CCTACACAATCGCTCAAGACGCGCAGATCAAATAATAGCG			
11477_carB_Rvdn	CTGCTCGTAAGGCATCAGACT			
11478_carB_Fwsc	CAAGGGAGCTGGACACTG			
11479_carB_Rvsc	CAACTTCGTTACTTACGGCC			
3746-Cm.3a	TCCTCCTTAGTTCCTATTCC			
3747-Cm.4a	GTCTTGAGCGATTGTGTAGG			

340